Axsome Therapeutics Inc [AXSM] stock prices are down -2.16% to $178.69 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AXSM shares have gain 16.30% over the last week, with a monthly amount glided 25.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on October 01, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $179. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $185 on June 03, 2025. Jefferies initiated its recommendation with a Buy and recommended $200 as its price target on April 07, 2025. Deutsche Bank started tracking with a Buy rating for this stock on February 11, 2025, and assigned it a price target of $176. In a note dated December 31, 2024, Mizuho reiterated an Outperform rating on this stock and revised its target price from $124 to $122.
The stock price of Axsome Therapeutics Inc [AXSM] has been fluctuating between $79.19 and $184.40 over the past year. Currently, Wall Street analysts expect the stock to reach $196.86 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $178.69 at the most recent close of the market. An investor can expect a potential return of 10.17% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
The Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 561.26M for trailing twelve months, representing a surge of 63.22%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.38%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -3.57 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 174.70 points at the first support level, and at 170.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 183.01, and for the 2nd resistance point, it is at 187.32.
Ratios To Look Out For
It’s worth pointing out that Axsome Therapeutics Inc [NASDAQ:AXSM]’s Current Ratio is 1.57. As well, the Quick Ratio is 1.50, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 16.05, the price to book ratio is 121.93.
Transactions by insiders
Recent insider trading involved Saad Mark E, Director, that happened on Dec 31 ’25 when 37577.0 shares were sold. Director, Saad Mark E completed a deal on Dec 31 ’25 to buy 37577.0 shares. Meanwhile, Chief Executive Officer TABUTEAU HERRIOT sold 49252.0 shares on Dec 02 ’25.
